Despite the relatively high long-term disease-free survival (DFS) rate for patients with
Hodgkin lymphoma (HL) with modern combination chemotherapy or combined modality …

Relapse remains a major cause of treatment failure after autotransplantation (auto-PBSCT)
for Hodgkin's disease (HD). The administration of non-crossresistant therapies during the …

Purpose A prospective multicenter trial evaluated a risk-adapted salvage treatment with
single or tandem autologous stem-cell transplantation (ASCT) for 245 Hodgkin's lymphoma …

Prior series have demonstrated that early relapsed (within 1 year) or refractory Hodgkin
lymphoma (HL) is associated with poor prognosis. To determine the outcome for patients …

ASCT results might well be implemented by improving the quality of the remission of patients
undergoing the procedure with more effective salvage protocols or by selecting those …

Autologous hematopoietic stem cell transplantation (ASCT) has become standard therapy
for primary refractory (PR REF) or relapsed (REL) Hodgkin's lymphoma (HL); however, more …

Background The purpose of this study was to assess prognostic factors and outcome of
patients with relapsed/refractory Hodgkin's lymphoma (HL) who received high-dose …

Newly diagnosed patients who have advanced-stage Hodgkin's lymphoma have an
excellent prognosis because most of them can be cured with initial treatment. In contrast, the …

The introduction of high-dose (HD) chemotherapy (CT) and autologous stem cell (ASCT) or
bone marrow transplant (ABMT) in the last two decades has improved the prognosis of …

The treatment of classic Hodgkin lymphoma (HL) is a success in onco-hematology. Despite
the high cure rate of HL with initial therapy, 5–10% of patients are primary refractory and 10 …